Roth Affirms Galena Biopharma (GALE) at 'Buy' Fllowing GALE-301 Phase 2a Update; 1000 mcg Seen as Optimal
Tweet Send to a Friend
Roth Capital affirms Galena Biopharma (NASDAQ: GALE) with a Buy rating and $8 price target after the company announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
